Corrigendum to “CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice” [Toxicon 215 (2022) 28–36]

Antivenom is the only safe and effective treatment to neutralize snake venom. Specific anti-venom used to treat snake bite is usually obtained from horses after hyperimmunization with crude snake venom in combination with Freund’s Adjuvant. Freund’s complete and incomplete adjuvant can cause seve...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fusco, Luciano Sebastián, Pascual, María Mercedes, Hernandez, David, Sánchez Vallecillo, María Fernanda, Arrieta, María Belén, Moron, Gabriel, Palma, Santiago, Maletto, Belkys Angélica, Leiva, Laura Cristina Ana
Formato: Artículo
Lenguaje:Inglés
Publicado: Elsevier 2025
Materias:
Acceso en línea:http://repositorio.unne.edu.ar/handle/123456789/59444
Aporte de:
id I48-R184-123456789-59444
record_format dspace
spelling I48-R184-123456789-594442025-12-16T14:59:52Z Corrigendum to “CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice” [Toxicon 215 (2022) 28–36] Fusco, Luciano Sebastián Pascual, María Mercedes Hernandez, David Sánchez Vallecillo, María Fernanda Arrieta, María Belén Moron, Gabriel Palma, Santiago Maletto, Belkys Angélica Leiva, Laura Cristina Ana CpG-ODN Snake venom Antivenom is the only safe and effective treatment to neutralize snake venom. Specific anti-venom used to treat snake bite is usually obtained from horses after hyperimmunization with crude snake venom in combination with Freund’s Adjuvant. Freund’s complete and incomplete adjuvant can cause severe local and sys- temic acute and chronic inflammation, its potentially severe inflammatory effects have led many researchers to seek alternative immunological adjuvants. CpG-ODN formulated in a 6-O-ascorbyl palmitate nanostructure (Coa-ASC16) was more efficient as adjuvant than CpG-ODN alone using ovalbumin (OVA) as an antigen model. Particularly, immunization of mice with OVA/CpG-ODN/Coa-ASC16 resulted in high OVA specific antibody titers and IFN-γ and IL-17 secretion compared to im- munization with OVA/CpG-ODN. First of all, we estimated the effect of Coa-ASC16 nanostructure preparation on venom activity. Additionally, in order to evaluate the immune response induced by this adjuvant strategy using Crotalus durissus terrificus (C. d. terrificus) venom (CdtV), we determined the titer of antibodies (IgG, IgG1 and IgG2) and their specificity. BALB/c mice were subcutaneously immunizated on days 0, 15 and 30 with CdtV/CpG-ODN/Coa-ASC16 or CdtV/Freund’s Adyuvant (complete first and incomplete-booster) (dose/mice: CdtV: 6–10 μg, CpG-ODN: 30 μg). On day 45 mice were sacrificed. The neutralizing ability of serum from animals immunized with CdtV/CpG-ODN/Coa-ASC16 or CdtV/Freund’s adjuvant was tested against PLA2 activity and lethality. In both immunized group mice, the antibody titers in plasma were high (1 × 105 ), with a similar IgG1/IgG2a ratio. The antibodies recognized phospholipase A2 and thrombin-like proteins, the main toxins from C. d. terrificus venom. Macroscopic and microscopic analysis at the site of injection of mice injected with Freund’s adjuvant showed local damage (with non-infectious abscesses) and hypertrophy of inguinal lymph nodes, whereas mice injected with CpG-ODN/Coa/ASC16 did not. Our results show that CpG-ODN/Coa- ASC16 produces a humoral response as strong and specific as Freund’s adjuvant, with minor or null local deleterious effect, demonstrating the potentiality and advisability of an alternative formulation as a new adjuvant option for future immunizations to produce C. d. terrificus antivenom. 2025-12-15T11:37:32Z 2025-12-15T11:37:32Z 2022-09-25 Artículo Fusco, Luciano Sebastián, et al., 2022. Corrigendum to “CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice” [Toxicon 215 (2022) 28–36]. Toxicon. Países Bajos: Elsevier, vol. 216, p. 114-114. E-ISSN 1879-3150. 0041-0101 http://repositorio.unne.edu.ar/handle/123456789/59444 eng https://doi.org/10.1016/j.toxicon.2022.07.002 openAccess http://creativecommons.org/licenses/by-nc-nd/2.5/ar/ application/pdf p. 114-114 application/pdf Elsevier Toxicon, 2022, vol. 216, p. 114-114.
institution Universidad Nacional del Nordeste
institution_str I-48
repository_str R-184
collection RIUNNE - Repositorio Institucional de la Universidad Nacional del Nordeste (UNNE)
language Inglés
topic CpG-ODN
Snake venom
spellingShingle CpG-ODN
Snake venom
Fusco, Luciano Sebastián
Pascual, María Mercedes
Hernandez, David
Sánchez Vallecillo, María Fernanda
Arrieta, María Belén
Moron, Gabriel
Palma, Santiago
Maletto, Belkys Angélica
Leiva, Laura Cristina Ana
Corrigendum to “CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice” [Toxicon 215 (2022) 28–36]
topic_facet CpG-ODN
Snake venom
description Antivenom is the only safe and effective treatment to neutralize snake venom. Specific anti-venom used to treat snake bite is usually obtained from horses after hyperimmunization with crude snake venom in combination with Freund’s Adjuvant. Freund’s complete and incomplete adjuvant can cause severe local and sys- temic acute and chronic inflammation, its potentially severe inflammatory effects have led many researchers to seek alternative immunological adjuvants. CpG-ODN formulated in a 6-O-ascorbyl palmitate nanostructure (Coa-ASC16) was more efficient as adjuvant than CpG-ODN alone using ovalbumin (OVA) as an antigen model. Particularly, immunization of mice with OVA/CpG-ODN/Coa-ASC16 resulted in high OVA specific antibody titers and IFN-γ and IL-17 secretion compared to im- munization with OVA/CpG-ODN. First of all, we estimated the effect of Coa-ASC16 nanostructure preparation on venom activity. Additionally, in order to evaluate the immune response induced by this adjuvant strategy using Crotalus durissus terrificus (C. d. terrificus) venom (CdtV), we determined the titer of antibodies (IgG, IgG1 and IgG2) and their specificity. BALB/c mice were subcutaneously immunizated on days 0, 15 and 30 with CdtV/CpG-ODN/Coa-ASC16 or CdtV/Freund’s Adyuvant (complete first and incomplete-booster) (dose/mice: CdtV: 6–10 μg, CpG-ODN: 30 μg). On day 45 mice were sacrificed. The neutralizing ability of serum from animals immunized with CdtV/CpG-ODN/Coa-ASC16 or CdtV/Freund’s adjuvant was tested against PLA2 activity and lethality. In both immunized group mice, the antibody titers in plasma were high (1 × 105 ), with a similar IgG1/IgG2a ratio. The antibodies recognized phospholipase A2 and thrombin-like proteins, the main toxins from C. d. terrificus venom. Macroscopic and microscopic analysis at the site of injection of mice injected with Freund’s adjuvant showed local damage (with non-infectious abscesses) and hypertrophy of inguinal lymph nodes, whereas mice injected with CpG-ODN/Coa/ASC16 did not. Our results show that CpG-ODN/Coa- ASC16 produces a humoral response as strong and specific as Freund’s adjuvant, with minor or null local deleterious effect, demonstrating the potentiality and advisability of an alternative formulation as a new adjuvant option for future immunizations to produce C. d. terrificus antivenom.
format Artículo
author Fusco, Luciano Sebastián
Pascual, María Mercedes
Hernandez, David
Sánchez Vallecillo, María Fernanda
Arrieta, María Belén
Moron, Gabriel
Palma, Santiago
Maletto, Belkys Angélica
Leiva, Laura Cristina Ana
author_facet Fusco, Luciano Sebastián
Pascual, María Mercedes
Hernandez, David
Sánchez Vallecillo, María Fernanda
Arrieta, María Belén
Moron, Gabriel
Palma, Santiago
Maletto, Belkys Angélica
Leiva, Laura Cristina Ana
author_sort Fusco, Luciano Sebastián
title Corrigendum to “CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice” [Toxicon 215 (2022) 28–36]
title_short Corrigendum to “CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice” [Toxicon 215 (2022) 28–36]
title_full Corrigendum to “CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice” [Toxicon 215 (2022) 28–36]
title_fullStr Corrigendum to “CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice” [Toxicon 215 (2022) 28–36]
title_full_unstemmed Corrigendum to “CpG-ODN formulated with a nanostructure as adjuvant for anticrotalic serum production. Studies in mice” [Toxicon 215 (2022) 28–36]
title_sort corrigendum to “cpg-odn formulated with a nanostructure as adjuvant for anticrotalic serum production. studies in mice” [toxicon 215 (2022) 28–36]
publisher Elsevier
publishDate 2025
url http://repositorio.unne.edu.ar/handle/123456789/59444
work_keys_str_mv AT fuscolucianosebastian corrigendumtocpgodnformulatedwithananostructureasadjuvantforanticrotalicserumproductionstudiesinmicetoxicon21520222836
AT pascualmariamercedes corrigendumtocpgodnformulatedwithananostructureasadjuvantforanticrotalicserumproductionstudiesinmicetoxicon21520222836
AT hernandezdavid corrigendumtocpgodnformulatedwithananostructureasadjuvantforanticrotalicserumproductionstudiesinmicetoxicon21520222836
AT sanchezvallecillomariafernanda corrigendumtocpgodnformulatedwithananostructureasadjuvantforanticrotalicserumproductionstudiesinmicetoxicon21520222836
AT arrietamariabelen corrigendumtocpgodnformulatedwithananostructureasadjuvantforanticrotalicserumproductionstudiesinmicetoxicon21520222836
AT morongabriel corrigendumtocpgodnformulatedwithananostructureasadjuvantforanticrotalicserumproductionstudiesinmicetoxicon21520222836
AT palmasantiago corrigendumtocpgodnformulatedwithananostructureasadjuvantforanticrotalicserumproductionstudiesinmicetoxicon21520222836
AT malettobelkysangelica corrigendumtocpgodnformulatedwithananostructureasadjuvantforanticrotalicserumproductionstudiesinmicetoxicon21520222836
AT leivalauracristinaana corrigendumtocpgodnformulatedwithananostructureasadjuvantforanticrotalicserumproductionstudiesinmicetoxicon21520222836
_version_ 1857347545247776768